NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
RiskLD is a physician-led startup out of Cleveland focused on improving maternity outcomes.
Chronic pain affects the mental health of young people and it requires continuous and complex self-management that often fails. Happyr Health supports teens with...
Mike Ricci leads Spect, a Y Combinator startup focused on combining eye-care diagnostics and artificial intelligence.
